The London Bioscience Innovation Centre
2 Royal College Street
NALIA was founded to develop and commercialise the NALIA array technology with broad applications in research, biomarker validation and point-of-care diagnosis and monitoring.
NALIA's technology provides arrays of multiple biomarkers in either a standard 96-well format or in a single-sample point-of-care format.
CEO: Nigel Davis, PhD, MBA
CSO: Prof Ivan Roitt FRS
Chairman: Berwyn Clarke, PhD.